KR20210114717A - A Composition for Preventing or Treating Metabolic Disorders Comprising a Tat Peptide Variant as an Active Ingredient - Google Patents

Abstract

The present invention relates to a pharmaceutical composition and a functional food composition which are for preventing or treating metabolic diseases, and comprise, as an active ingredient, a Tat peptide variant in which internal residue of a certain length is replaced by an aliphatic amino carboxylic acid. The composition of the present invention retains a fat reduction effect of natural Tat peptide and has remarkably increased water solubility and yield, thereby being able to be usefully used as a composition for treating metabolic diseases that is easier to produce and has better biocompatibility.

Description

A composition for preventing or treating metabolic diseases comprising a Tat peptide variant as an active ingredient {A Composition for Preventing or Treating Metabolic Disorders Comprising a Tat Peptide Variant as an Active Ingredient}

The present invention relates to a composition for preventing or treating metabolic diseases comprising, as an active ingredient, a Tat peptide variant in which an internal residue of a certain length is substituted with an aliphatic amino carboxylic acid.

Obesity is a metabolic disease caused by an imbalance between caloric intake and consumption, and is directly caused by an increase in the size (hypertrophy) or an increase in the number (hyperplasia) of fat cells in the body. Obesity is not only the most common nutritional disorder in Western society, but also in recent years in Korea, the frequency of obesity is rapidly increasing due to the improvement of diet and westernization of lifestyles due to economic development. Although the population is 5.3% of the total population, which is not higher than the OECD average obesity rate, the obesity rate for boys and adolescents (26%, including overweight) is higher than the OECD average (25.6%), and the obesity rate is increasing every year. It is predicted that the number of highly obese population will double by 2030. In addition, the socioeconomic loss due to obesity was 9.2 trillion won in 2015, doubling in the last 10 years, and it is expected to accelerate further due to aging.

Metabolic syndrome, which accompanies diabetes, hypertension, lipid metabolism abnormality, and insulin resistance, has emerged as a major disease group that threatens human health due to its high prevalence. It is considered a serious health problem, and enormous human and material capabilities are being put into solving it. The diseases belonging to the metabolic syndrome increase the risk of mutual occurrence, and are a group of common diseases that are related to plural metabolic changes such as aging, stress, and decreased immune function.

On the other hand, infection by HIV-1 (Human Immunodeficiency Virus-1) is the etiology of AIDS (Acquired Immunodeficiency Syndrome), and metabolic abnormalities, weight loss, anorexia and damage to body tissues are the main clinical symptoms of HIV infection. These changes, collectively called rapid weight loss (wasting), are one of the leading causes of morbidity and death in AIDS patients.

Tat is a small nuclear transactivation protein encoded by HIV-1, whose amino acid sequence is conserved in all primate lentiviruses (Myers et al., 1996). Tat is one of the most important regulators of HIV-1 transcription and replication, and has been known to be responsible for several intracellular biological regulatory functions, such as T-lymphocyte activation, apoptosis, and regulation of gene expression.

Numerous papers and patent documents are referenced throughout this specification and their citations are indicated. The disclosure contents of the cited papers and patent documents are incorporated herein by reference in their entirety to more clearly describe the level of the technical field to which the present invention pertains and the content of the present invention.

Patent Document 1. Republic of Korea Application No. 10-2015-0187948

The present inventors strive to develop an efficient therapeutic composition that has excellent therapeutic activity for metabolic diseases including obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome, and has fewer side effects and is easy to synthesize even during long-term administration. did. As a result, the CDK9 binding site and the cyclin T1 binding site, which play a key role in fat reduction among the HIV-1 derived full-length Tat peptides (72a.a) having antiobesity activity, were identified, and the domains between them were preserved. By substituting 11 amino acid residues with aliphatic amino carboxylic acids, it was found that water solubility and yield were significantly increased while maintaining the anti-obesity activity of the Tat peptide, thereby completing the present invention.

Accordingly, an object of the present invention is to provide a pharmaceutical composition and a functional food composition for preventing or treating metabolic disorders.

Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention, claims and drawings.

According to one aspect of the present invention, the present invention relates to obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome comprising a compound represented by the following general formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient ( Insulin resistance syndrome) provides a pharmaceutical composition for preventing or treating a metabolic disorder selected from the group consisting of:

general formula 1

In the above general formula, R ₁ is a polypeptide having the amino acid sequence of SEQ ID NO: 1 or a partial fragment of its C-terminal region, and R ₂ is a polypeptide having the amino acid sequence of SEQ ID NO: 2 or its N-terminus It is a partial fragment of a region, and n is an integer from 3 to 7.

The present inventors strive to develop an efficient therapeutic composition that has excellent therapeutic activity for metabolic diseases including obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome, and has fewer side effects and is easy to synthesize even during long-term administration. did. As a result, the CDK9 binding site and the cyclin T1 binding site, which play a key role in fat reduction among the HIV-1 derived full-length Tat peptides (72a.a) having antiobesity activity, were identified, and the domains between them were preserved. When 11 amino acid residues are substituted with the aliphatic amino carboxylic acid of Formula 1, water solubility and yield are remarkably increased while maintaining the anti-obesity activity of the natural Tat peptide, making it easier to produce and efficient treatment with excellent biocompatibility It has been found that the composition can be used.

According to the present invention, the amino acid sequence of the first sequence in SEQ ID NO: 1 is residues 1-37 of the Tat peptide (72a.a), and the amino acid sequence of the second sequence in SEQ ID NO: 2 is residues 48-72 of the Tat peptide. Therefore, Formula 1 is a mutant Tat peptide in which 11 residues (38 to 48) between the basic PTD domain, which is the CDK9 binding site, and the cysteine zinc finger domain, which is the cyclin T1 binding site, are substituted with aliphatic amino carboxylic acids.

As used herein, the term “metabolic disease” conceptualizes the phenomenon in which the risk factors of various cardiovascular diseases and type 2 diabetes, which are caused by metabolic abnormalities, cluster with each other as one disease group, and insulin resistance and related complex and It is a concept that encompasses various metabolic abnormalities and clinical aspects.

As used herein, the term “obesity” refers to a state in which the amount of energy intake exceeds energy consumption over a long period of time and the excess energy is stored as fat, resulting in an excess of adipose tissue in the body. Usually, if the body mass index (Body mass index: weight (kg)/[height (m)] ² ) is 25 or more, it is defined as fertilely obese.

As used herein, the term “diabetes” refers to a chronic disease characterized by a relative or absolute lack of insulin resulting in glucose-intolerance. Diabetes treated or prevented by the composition of the present invention includes all types of diabetes, for example, type 1 diabetes, type 2 diabetes, and hereditary diabetes. Type 1 diabetes is insulin-dependent diabetes mellitus, mainly caused by destruction of β-cells. Type 2 diabetes is non-insulin-dependent diabetes mellitus, caused by insufficient insulin secretion after a meal or by insulin resistance.

As used herein, the term “dyslipidemia” refers to a pathologic condition in which the level of fat concentration in the blood is outside the normal range, for example, hypercholesterolemia, hypertriglyceridemia, low-HDL-cholesterol. In addition to hyperlipidemia and hyper-LDL-cholesterolemia, it includes all abnormal lipid states caused by abnormal lipoprotein metabolism.

As used herein, the term “fatty liver” refers to a state in which fat is accumulated in hepatocytes in an excessive amount due to a disorder of fat metabolism in the liver, which causes various diseases such as angina pectoris, myocardial infarction, stroke, arteriosclerosis, fatty liver and pancreatitis.

As used herein, the term “insulin resistance” refers to a state in which cells cannot effectively burn glucose because the function of insulin to lower blood sugar is low. When insulin resistance is high, the body makes too much insulin, which can lead to high blood pressure or dyslipidemia, as well as heart disease and diabetes. In particular, in type 2 diabetes mellitus, an increase in insulin in muscle and adipose tissue is not noticed, and the action of insulin does not occur. The term “insulin resistance syndrome” is a concept that collectively refers to diseases induced by insulin resistance. Cell resistance to insulin action, hyperinsulinemia, and increase in very low density lipoprotein (VLDL) and triglycerides, high density It refers to a disease characterized by a decrease in high density lipoprotein (HDL) and hypertension, and is a concept recognized as a risk factor for cardiovascular disease and type 2 diabetes (Reaven GM, Diabetes, 37: 1595-607, (1988)).

As used herein, the term “pharmaceutically acceptable salt” includes salts derived from pharmaceutically acceptable inorganic acids, organic acids, or bases. Examples of suitable acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, trifluoroacetic acid, citric acid, methane sulfonic acid, formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and the like. Salts derived from suitable bases may include alkali metals such as sodium, alkaline earth metals such as magnesium, and ammonium and the like.

According to a specific embodiment of the present invention, n is an integer of 5 to 7, and more specifically, 6.

According to a specific embodiment of the present invention, the dyslipidemia prevented or treated with the composition of the present invention is hyperlipidemia.

As used herein, the term “hyperlipidemia” refers to a disease caused by maintaining a high lipid concentration in the blood because fat metabolism such as triglycerides and cholesterol is not properly performed. More specifically, hyperlipidemia includes hypercholesterolemia or hypertriglyceridemia with a high incidence in a state in which lipid components such as triglycerides, LDL cholesterol, phospholipids and free fatty acids in the blood are increased.

According to a specific embodiment of the present invention, the fatty liver to be prevented or treated by the composition of the present invention is non-alcoholic fatty liver.

As used herein, the term “non-alcoholic fatty liver (NAFL)” refers to a disease in which an excessive amount of fat is accumulated in liver cells regardless of alcohol absorption, and includes simple fatty liver (steatosis) and non-alcoholic non-alcoholic steatohepatitis (NASH). Although simple fatty liver has a good clinical prognosis, NASH with inflammation or fibrosis is a progressive liver disease and is recognized as a progenitor disease that causes cirrhosis or liver cancer. Obesity and insulin resistance are major risk factors for nonalcoholic fatty liver disease. Risk factors for the progression of liver fibrosis include obesity (BMI > 30), blood liver function index ratio (AST/ALT > 1), and diabetes. can 69-100% of nonalcoholic fatty liver patients are obese, and 20-40% of obese patients have nonalcoholic fatty liver. This is because obesity is the most important risk factor for nonalcoholic liver disease.

As used herein, the term “prevention” refers to inhibiting the occurrence of a disease or disease in a subject who has never been diagnosed as having a disease or disease, but is likely to be afflicted with the disease or disease.

As used herein, the term “treatment” refers to (a) inhibiting the development of a disease, disorder or condition; (b) alleviation of the disease, condition or condition; or (c) eliminating the disease, condition or symptom. When the composition of the present invention is administered to a subject, it reduces the weight of adipose tissue, increases insulin and glucose sensitivity, and greatly reduces the expression of proteins involved in adipogenesis and cholesterol synthesis, thereby reducing metabolic disease symptoms due to excessive fat accumulation. It plays a role in inhibiting, eliminating, or alleviating development. Accordingly, the composition of the present invention may be a composition for treating these diseases by itself, or may be administered together with other pharmacological ingredients and applied as a therapeutic adjuvant for the above diseases. Accordingly, as used herein, the term “treatment” or “therapeutic agent” includes the meaning of “therapeutic adjuvant” or “therapeutic adjuvant”.

As used herein, the term “administration” or “administering” refers to directly administering a therapeutically effective amount of the composition of the present invention to a subject so that the same amount is formed in the subject's body.

In the present invention, the term “therapeutically effective amount” refers to the content of the composition in which the pharmacological component in the composition is sufficient to provide a therapeutic or prophylactic effect to an individual to whom the pharmaceutical composition of the present invention is to be administered. prophylactically effective amount”.

As used herein, the term “subject” includes, without limitation, humans, mice, rats, guinea pigs, dogs, cats, horses, cattle, pigs, monkeys, chimpanzees, baboons or rhesus monkeys. Specifically, the subject of the present invention is a human.

According to a specific embodiment of the present invention, R ₁ in Formula 1 is a polypeptide having the amino acid sequence of SEQ ID NO: 1 or 18 or more consecutive from C-terminus to N-terminal direction of SEQ ID NO: 1 have amino acid residues. More specifically, the fragment is a polypeptide having the amino acid sequence of SEQ ID NO: 3 .

According to a specific embodiment of the present invention, R ₂ of Formula 1 is a polypeptide having the amino acid sequence of SEQ ID NO: 2 or 9 or more consecutive from the N-terminus to the C-terminus of the second sequence of SEQ ID NO: 2 have amino acid residues. More specifically, the fragment has the amino acid sequence of SEQ ID NO:4.

According to the present invention, the amino acid sequence of SEQ ID NO: 3 is 20 to 37 residues of Tat peptide (72a.a), and the amino acid sequence of SEQ ID NO: 4 is 49 to 57 residues of Tat peptide.

When the composition of the present invention is prepared as a pharmaceutical composition, the pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier.

Pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention are commonly used in formulation, and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like. it's not going to be The pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, and the like, in addition to the above components. Suitable pharmaceutically acceptable carriers and agents are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).

The pharmaceutical composition of the present invention may be administered orally or parenterally, and specifically may be administered orally, intravenously, subcutaneously or intraperitoneally.

A suitable dosage of the pharmaceutical composition of the present invention is variously prescribed depending on factors such as formulation method, administration method, age, weight, sex, pathological condition, food, administration time, administration route, excretion rate and reaction sensitivity of the patient. can be A preferred dosage of the pharmaceutical composition of the present invention is within the range of 0.001-100 mg/kg for adults.

The pharmaceutical composition of the present invention is prepared in unit dosage form by formulating using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily carried out by a person of ordinary skill in the art to which the present invention pertains. or may be prepared by incorporation into a multi-dose container. In this case, the formulation may be in the form of a solution, suspension, syrup, or emulsion in oil or aqueous medium, or may be in the form of an extract, powder, powder, granule, tablet or capsule, and may additionally include a dispersant or stabilizer.

According to another aspect of the present invention, the present invention relates to obesity, diabetes,

There is provided a food composition for alleviating or alleviating a metabolic disorder selected from the group consisting of dyslipidemia, fatty liver and insulin resistance syndrome:

general formula 1

Since the synthetic peptide of Formula 1 and the metabolic disease in which symptoms are improved or alleviated using the same have already been described above, description thereof will be omitted to avoid excessive overlap.

As used herein, the term “food pharmaceutically acceptable salt” refers to a salt in a form that can be used in a food composition among salts in which cations and anions are combined by electrostatic attraction, and specific examples thereof include the above-mentioned “pharmaceutically acceptable salts”. acceptable salts”.

When the composition of the present invention is prepared as a food composition, it may include not only the compound of the present invention as an active ingredient, but also carbohydrates, seasonings and flavoring agents that are commonly added during food production. Examples of carbohydrates include monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; polysaccharides such as dextrin and cyclodextrin; and sugar alcohols such as xylitol, sorbitol, and erythritol, but are not limited thereto. As the flavoring agent, natural flavoring agents (taumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used. For example, when the food composition of the present invention is prepared as a drink, citric acid, high fructose, sugar, glucose, acetic acid, malic acid, fruit juice, licorice root extract, jujube extract, licorice extract, etc. are added in addition to the pine bark extract, which is the active ingredient of the present invention. can be included as

The features and advantages of the present invention are summarized as follows:

(a) The present invention provides a pharmaceutical composition and a functional food composition for the prevention or treatment of metabolic diseases comprising a Tat peptide variant in which an internal residue of a certain length is substituted with an aliphatic amino carboxylic acid as an active ingredient.

(b) the composition of the present invention maintains the fat reduction effect of the natural Tat peptide as it is, and the water solubility and yield are remarkably increased, making it easier to produce and can be usefully used as a composition for treating metabolic diseases with superior biocompatibility .

1 is a diagram showing the crystal structure of Tat-cycline T1-CDK9 complex X-ray diffraction analysis. Tat's cysteine zinc finger domain (IV, red) and basic domain (II, purple) are linked by a linear peptide.
Figure 2 is a diagram showing the structure of a novel polypeptide (X-FAT8) newly designed based on the study of the domain function of the Tat protein. Eleven amino acid polypeptides (red) are substituted with one 8-amino-octanoic acid.
Fig. 3 shows that X-FAT8 and X-FAT5 inhibit the differentiation of 3T3-L1 adipocyte precursor cells and suppress adipogenesis (Fig. 3a and 3b), and inhibit the synthesis and accumulation of oleic acid in HepG2, a human hepatocyte (Fig. 3c) is shown respectively.
4 shows the results of western blotting analysis showing that the expression of a protein involved in the regulation of adipose tissue differentiation, adipogenesis, and cholesterol synthesis in human HepG2 cells is reduced by the administration of X-FAT8.
5 is a diagram showing significant weight loss according to X-FAT8 treatment in a DIO obese mouse model.
6 is a diagram showing the change in the amount of food intake after X-FAT8 treatment in a DIO obese mouse model.
7 is a diagram showing the state of abdominal fat and changes in epididymal brown fat (eWAT), liver tissue and brown fat (BAT) after intraperitoneal administration of X-FAT8 in a DIO obese mouse model.
8 is a diagram showing the results of GTT (glucose tolerance test) (FIG. 8a) and ITT (insulin tolerance test) to investigate changes in glucose homeostasis after intraperitoneal administration of X-FAT8 in a DIO obese mouse model, respectively.

Hereinafter, the present invention will be described in more detail through examples. These examples are only for illustrating the present invention in more detail, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples according to the gist of the present invention. .

Example

animal model

For the in vivo efficacy experiment of the anti-obesity peptide of the present invention, a DIO (diet induced obese) obesity model mouse (male, C57BL/6J DIO 12 weeks old, JAX LAB, Central Laboratory Animal Import Source) was used, and 60% high fat for DIO purpose food was supplied. All experimental groups were divided into three groups and the anti-obesity peptide of the present invention was administered intraperitoneally.

Screening of novel anti-obesity peptides

In a previous study, the present inventors found that the rapid weight loss (slim disease) of 20 to 30% (1-3) observed between 0.5 and 2 years during HIV-1 virus infection (1-3) was caused by Tat peptide, one of the HIV-1 gene products. It was confirmed that it is caused by lipodystrophy and discovered the Tat-38 domain (TACTNCYCAKCCFH-FITKALGISYG-RAKRRARQRRR) having an obesity inhibitory activity through a domain mapping study of the Tat peptide (US Patent No. 10,300,111). arc)(4). It was confirmed that the discovered Tat-38 peptide decreased the weight of adipose tissue and increased insulin and glucose sensitivity.

In the present invention, it was attempted to develop an improved peptide of Tat-38, which has superior pharmacological properties and is easier to synthesize than Tat-38. The present inventors hypothesized that the lipid metabolism regulatory activity of Tat-38 is the result of regulating gene expression through the formation of CDK9-cyclin T1-Tat conjugate, which is important for its action as a transcription factor, and the crystal structure of the complex of three proteins X-ray diffraction analysis was performed for the As shown in Figure 1, the cysteine zinc finger domain (red) and basic PTD domain (purple) of Tat interact with cyclins T1 and CDK9, respectively, and these domains are linked to each other through linear 10 amino acid residues. was confirmed. Therefore, based on the fact that the spatial distance between these domains is similar to the length of pentane or octane in which 5 to 8 carbons are linearly bonded, 10 amino acids are removed and 5-amino phantanic acid ( 5-amino-pentanoic acid) and 8-amino octanoic acid (8-amino octanoic acid) were designed to replace the peptide (Fig. 2). The present inventors named these modified Tat-38 peptides as X-FAT5 and X-FAT8, respectively.

Characterization of X-FAT8

After verifying drug efficacy by synthesizing X-FAT8 on a small scale, large-capacity synthesis (10g) and dispensing (5mg/vial, vacuum) were successful in preparation for demands such as preclinical related experiments. X-FAT8 showed a synthesis yield of 10 times higher than that of Tat-38, and it was confirmed that it was very well dissolved in water.

cell experiment

For adipocyte culture, DMEM (glucose 4.5 g/liter, GibcoBRL-Cat# 11995-065) medium containing calf serum (Gibco-BRL-Cat# 16170-078) at a final concentration of 10% was used. . When the adipocytes grow to about 70-80% of the culture flask area, the cells are separated from the incubator by treatment with 0.05% Trypsin-EDTA (GibcoBRL-Cat#15400-054), diluted in a medium, and the cell suspension is stirred at 1,200 rpm, After centrifugation for 2 minutes, the supernatant was removed and suspended by addition of fresh medium. After measuring the number of cells, it was divided into 5 x 10 ⁴ cells/culture dish in a 60 mm round culture dish. When the cells are attached, the medium is exchanged with 10% FBS/DMEM (Fetal Bovine Serum, GibcoBRL-Cat#10437-028; Dulbecco's Modified Egales Medium; DMEM/glucose 4.5 g/liter, GibcoBRL-Cat#11995-065). Cultures were carried out until the incubator was confluent. Cells were cultured in medium for differentiation; 1 μl of differentiation cocktail (3T3-L1 differentiation kit, cat # DIF001, Sigma) containing isobutylmethylxanthine;I BMX, insulin, dexamethasone and rosiglitazone was added to 1 ml 10% FBS/DMEM culture medium and added After adding 1 μM, 3 μM, and 10 μM to X-FAT8, respectively, it was cultured for 2 days (day 0). The old medium was replaced with 10% FBS/DMEM medium supplemented with 1 μg/ml insulin, and 1 μM, 3 μM and 10 μM of X-FAT8 were added to the medium, and cultured for 2 more days (day 2). After changing to the medium containing insulin, it was observed that fat was accumulated in the cells in the control group. In addition, 1 μM, 3 μM and 10 μM of X-FAT8 were added to the culture medium exchanged with 10% FBS/DMEM medium, and cultured for 2 days, 4 days, 6 days, and 8 days. Differentiation was also confirmed through microscopic observation of the treated cells and Oil Red O staining. While completely differentiated adipocytes were observed after 2 days in the control group, in the experimental group in which 1 μM, 3 μM and 10 μM of X-FAT8 was added, 3T3-L1 differentiation into adipocytes and adipogenesis were significantly inhibited in a dose-dependent manner by X-FAT8. became (Fig. 3a). In addition, as a result of performing Oil Red O staining in the same process using 1 μM and 10 μM of X-FAT5, it was also confirmed that 3T3-L1 differentiation into adipocytes and adipogenesis were significantly inhibited ( FIG. 3b ).

In addition, HepG2, a human hepatocyte, significantly increased intracellular fat accumulation in the presence of oleic acid, and it was confirmed that the administered X-FAT8 inhibited fat accumulation in HepG2 liver-derived cells very effectively ( FIG. 3c ).

In addition, it is estimated that the proteins changed by X-FAT8 treatment of HepG2 cells are proteins involved in adipocyte differentiation, adipogenesis, cholesterol synthesis, etc. Expression was analyzed by Western blotting. HepG2 cells were treated with X-FAT8 (10 μM), the cell extract (50 μg) was separated by 8% SDS-PAGE, and ? After that, several antibodies ((PCSK9, custom made, Yonsei University College of Medicine; other antibodies manufactured by Santa Cruiz; SC-8984; PPAR-γ, SC7273; GAPDH, SC-32233; C/EBPa (14a.a). SSC) -61; SREBP-2, SC271616; PGC-1α (H300), SC-13067))), and as a result of examining the expression of the protein, it was found that their expression was significantly reduced ( FIG. 4 ). It was confirmed that the action of X-FAT8 to reduce intracellular fat can be applied as a useful therapeutic composition for various metabolic diseases caused by abnormal lipid metabolism.

Obese mouse model experiment

For the obese mouse model (DIO) induced by a high fat diet, X-FAT8 was administered at 1 mg/ea once every two days for 34 days. As a result, it showed a weight loss effect of 10-15% (FIG. 5), and no statistically significant difference was observed in the amount of food consumed (FIG. 6). After completion of X-FAT8 administration, mice were sacrificed and the condition of organs and visceral fat were observed. As a result, no specific organ abnormalities were observed, and it was confirmed that the size of the epididymal white fat (eWAT) was significantly reduced in the X-FAT8 administration group (FIG. 7).

GTT (glucose tolerance test) and ITT (insulin tolerance test) were performed to investigate the presence or absence of metabolic abnormalities. As a result of GTT, it was found that the blood glucose concentration was lower than that of the control group and reached the equilibrium state more quickly (FIG. 8a). On the other hand, there was no significant difference in insulin sensitivity (Fig. 8b). Through this, it was confirmed that X-FAT8 can be used as a therapeutic composition for various lipid metabolism abnormalities including obesity.

As described above in detail a specific part of the present invention, for those of ordinary skill in the art, this specific description is only a preferred embodiment, and it is clear that the scope of the present invention is not limited thereto. Accordingly, the substantial scope of the present invention will be defined by the appended claims and their equivalents.

<110> Industry-Academic Cooperation Foundation, Yonsei University <120> A Composition for Preventing or Treating Metabolic Disorders Comprising a Tat Peptide Variant as an Active Ingredient <130> HPC-9191 <160> 5 <170> KoPatentIn 3.0 <210> 1 <211> 37 <212> PRT <213> Human immunodeficiency virus type 1 <400> 1 Met Glu Pro Val Asn Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser 1 5 10 15 Gln Pro Lys Thr Ala Cys Thr Asn Cys Tyr Cys Ala Lys Cys Cys Phe 20 25 30 His Cys Gln Val Cys 35 <210> 2 <211> 24 <212> PRT <213> Human immunodeficiency virus type 1 <400> 2 Arg Ala Lys Arg Arg Gln Arg Arg Arg Pro Pro Gln Gly Ser Gln Thr 1 5 10 15 His Gln Val Ser Leu Ser Lys Gln 20 <210> 3 <211> 18 <212> PRT <213> Human immunodeficiency virus type 1 <400> 3 Thr Ala Cys Thr Asn Cys Tyr Cys Ala Lys Cys Cys Phe His Cys Gln 1 5 10 15 Val Cys <210> 4 <211> 9 <212> PRT <213> Human immunodeficiency virus type 1 <400> 4 Arg Ala Lys Arg Arg Gln Arg Arg Arg 1 5 <210> 5 <211> 72 <212> PRT <213> Human immunodeficiency virus type 1 <400> 5 Met Glu Pro Val Asn Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser 1 5 10 15 Gln Pro Lys Thr Ala Cys Thr Asn Cys Tyr Cys Ala Lys Cys Cys Phe 20 25 30 His Cys Gln Val Cys Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr Gly 35 40 45 Arg Ala Lys Arg Arg Gln Arg Arg Arg Pro Pro Gln Gly Ser Gln Thr 50 55 60 His Gln Val Ser Leu Ser Lys Gln 65 70

Claims (18)

Metabolism selected from the group consisting of obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome comprising a compound represented by the following general formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient A pharmaceutical composition for the prevention or treatment of a metabolic disorder:
general formula 1

In the above general formula, R ₁ is a polypeptide having the amino acid sequence of SEQ ID NO: 1 or a partial fragment of its C-terminal region, and R ₂ is a polypeptide having the amino acid sequence of SEQ ID NO: 2 or its N-terminus It is a partial fragment of a region, and n is an integer from 3 to 7.
The composition of claim 1, wherein n is an integer of 5 to 7.
3. The composition of claim 2, wherein n is 6.
The composition of claim 1, wherein the dyslipidemia is hyperlipidemia.
The composition according to claim 1, wherein the fatty liver is non-alcoholic fatty liver.
The method according to claim 1, wherein R ₁ is a polypeptide having the amino acid sequence of SEQ ID NO: 1 or a fragment having 18 or more amino acid residues continuous from the C-terminus to the N-terminus of SEQ ID NO: 1 Characterized composition.
The composition according to claim 6, wherein the fragment is a polypeptide having the amino acid sequence of SEQ ID NO:3.
The method according to claim 1, wherein R ₂ is a polypeptide having the amino acid sequence of SEQ ID NO: 2 or a fragment having 9 or more amino acid residues consecutive from the N-terminus to the C-terminus of SEQ ID NO: 2 Characterized composition.
The composition according to claim 8, wherein the fragment is a polypeptide having the amino acid sequence of SEQ ID NO:4.
Metabolism selected from the group consisting of obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome comprising a compound represented by the following general formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient A food composition for alleviating or alleviating a metabolic disorder:
general formula 1

In the above general formula, R ₁ is a polypeptide having the amino acid sequence of SEQ ID NO: 1 or a partial fragment of its C-terminal portion, and R ₂ is a polypeptide having the amino acid sequence of SEQ ID NO: 2 or its N-terminus It is a partial fragment of a region, and n is an integer from 3 to 7.
11. The composition of claim 10, wherein n is an integer of 5 to 7.
12. The composition of claim 11, wherein n is 6.
The composition of claim 10, wherein the dyslipidemia is hyperlipidemia.
11. The composition of claim 10, wherein the fatty liver is non-alcoholic fatty liver.
11. The method of claim 10, wherein R ₁ is a polypeptide having the amino acid sequence of SEQ ID NO: 1 or a fragment having 18 or more amino acid residues continuous from the C-terminus to the N-terminus of SEQ ID NO: 1 Characterized composition.
The composition according to claim 15, wherein the fragment is a polypeptide having the amino acid sequence of SEQ ID NO:3.
11. The method of claim 10, wherein R ₂ is a polypeptide having the amino acid sequence of SEQ ID NO: 2 or a fragment having 9 or more amino acid residues continuous from the N-terminus to the C-terminal direction of the second sequence of SEQ ID NO: 2 Characterized composition.
18. The composition of claim 17, wherein the fragment is a polypeptide having the amino acid sequence of SEQ ID NO:4.

Images